Search results for "Blood Platelets"

showing 8 items of 168 documents

In vivo effects of intravascularly applied Escherichia coli hemolysin: dissociation between induction of granulocytopenia and lethality in monkeys.

1993

The effects of intravascular application of endotoxin-depleted Escherichia coli hemolysin (HlyA) was studied in rabbits and monkeys. In rabbits, bolus application of HlyA calculated to effect final blood levels of approximately 2-3 HU/ml (200-300 ng/ml) caused an acute fall of polymorphonuclear blood leukocytes to less than 20% of starting levels within 5 min. Additionally, platelet counts dropped to approximately 30% of starting levels, whereas lymphocyte counts varied considerably and seldom fell to less than 50%. Nine out ten animals that received 2-4 HU/ml toxin died within 90 min post application. These animals presented with signs of acute respiratory failure and post mortem inspectio…

Microbiology (medical)Blood Plateletsmedicine.medical_specialtyPathologyLymphocyteImmunologyBacterial ToxinsSpleenBlood PressurePulmonary EdemaBiologyPulmonary sequestrationLethal Dose 50Hemolysin ProteinsBacterial ProteinsIn vivoInternal medicinemedicineEscherichia coliImmunology and AllergyAnimalsLungLeukopeniaLungDose-Response Relationship DrugPancreatic ElastaseEscherichia coli ProteinsElastaseGeneral Medicinemedicine.diseasePulmonary edemaBlood Cell CountCapillariesMacaca fascicularisEndocrinologymedicine.anatomical_structureInjections Intra-ArterialLiverInjections IntravenousRabbitsmedicine.symptomSpleenAgranulocytosisGranulocytesMedical microbiology and immunology
researchProduct

New pathways of increased cardiovascular risk in depression: a pilot study on the association of high-sensitivity C-reactive protein with pro-atheros…

2013

Abstract Background An elevation of inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) can be found in patients with depressive disorders. Inflammatory processes are known to influence atherosclerosis and might also mediate the link between depression and diabetes. The present study aimed at comparing hs-CRP and its relationship with atherogenic platelet markers in patients with type 2 diabetes (TD2) and/or newly diagnosed major depression (MD). Methods Hs-CRP concentrations in 24 patients with TD2, 21 patients with MD (diagnosed according to ICD-10 and DSM-IV), 19 patients with TD2 and comorbid MD, and 25 healthy controls were compared using analysis of variance. The…

OncologyAdultBlood PlateletsMalemedicine.medical_specialtyCD40 LigandMedizinPilot ProjectsType 2 diabetesDiseaseComorbidityRisk FactorsInternal medicineDiabetes mellitusmedicineHumansPlateletDepression (differential diagnoses)Depressive Disorder MajorCD40biologybusiness.industryC-reactive proteinMiddle Agedmedicine.diseaseAtherosclerosisPsychiatry and Mental healthClinical PsychologyEndocrinologyC-Reactive ProteinDiabetes Mellitus Type 2Cardiovascular DiseasesCase-Control Studiesbiology.proteinFemaleAnalysis of variancebusinessBiomarkersJournal of affective disorders
researchProduct

Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.

2017

The diagnosis of essential thrombocythemia and polycythemia vera is often made during a thrombotic event which can be serious. Philadelphia-negative chronic myeloproliferative neoplasia patients have an increased thrombotic risk. This is assessed using various scoring systems but these are far from ideal and individual risk. The currend trend to personalised medicine requires finding the most useful thrombotic risk biomarker in these patients. Routine tests for coagulation do not take account of both pro- and anti-coagulant factors which is why these tests are not useful in patients with Philadelphia-negative myeloproliferative neoplasms. Thrombin generation reflects more accurately the bal…

OncologyBlood PlateletsPathologymedicine.medical_specialtylcsh:Medicinemyeloproliferative neoplasmsGeneral Biochemistry Genetics and Molecular BiologyLeukemia Myeloid Chronic Atypical BCR-ABL NegativeDiagnosis Differential03 medical and health sciences0302 clinical medicinePolycythemia verapolycythemia veraCell-Derived MicroparticlesRisk Factorshemic and lymphatic diseasesInternal medicinemedicineBiomarkers TumorHumansThrombophiliaPlateletjak2 v617fMyeloproliferative neoplasmessential thrombocythemiaEssential thrombocythemiabusiness.industrylcsh:RThrombinThrombosispersonalized medicineJanus Kinase 2medicine.diseaseThrombosisCoagulationthrombin generation030220 oncology & carcinogenesisplateletsBiomarker (medicine)Personalized medicinebusinessthrombotic risk030215 immunologyBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
researchProduct

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer

2018

Background: Serum levels of neutrophils, platelets, and lymphocytes have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer (BC). Objective: To evaluate the prognostic role of the combination of the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) in patients with high-risk non–muscle-invasive urothelial BC (NIMBC). Design, setting, and participants: A total of 1151 NMIBC patients who underwent first transurethral resection of the bladder tumor (TURBT) at 13 academic institutions between January 1, 2002 and December 31, 2012 were included in this analysis. The median follow-up was 48 mo.…

OncologyMaleBladder cancer; Lymphocyte/monocyte ratio; Neutrophil/lymphocyte ratio; Platelet/lymphocyte ratio; Prognosis; Aged; Biomarkers Tumor; Blood Platelets; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Inflammation; Lymphocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Prognosis; Risk Factors; Urinary Bladder NeoplasmsNeutrophilsmedicine.medical_treatmentLymphocyte:Medicina Básica [Ciências Médicas]Prognosis.030232 urology & nephrologyMonocyteMonocytesSettore MED/24 - Urologia0302 clinical medicineRisk FactorsLymphocytesStage (cooking)Framingham Risk ScoreTumorNeutrophilBladder cancerPrognosis3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisNeutrophil/lymphocyte ratioCiências Médicas::Medicina BásicaDisease ProgressionLymphocyteFemalemedicine.symptomHumanBlood Plateletsmedicine.medical_specialtyPlatelet/lymphocyte ratioPrognosiUrologyInflammationCystectomyFollow-Up StudieCystectomy03 medical and health sciencesInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLymphocyte CountAgedInflammationCarcinoma Transitional CellBladder cancerScience & Technologybusiness.industryProportional hazards modelRisk FactorCarcinomaLymphocyte/monocyte ratioImmunotherapymedicine.diseaseUrinary Bladder NeoplasmsBlood PlateletSurgeryTransitional CellbusinessBiomarkersFollow-Up Studies
researchProduct

What Can Proteomics Tell Us About Platelets?

2014

More than 130 years ago, it was recognized that platelets are key mediators of hemostasis. Nowadays, it is established that platelets participate in additional physiological processes and contribute to the genesis and progression of cardiovascular diseases. Recent data indicate that the platelet proteome, defined as the complete set of expressed proteins, comprises >5000 proteins and is highly similar between different healthy individuals. Owing to their anucleate nature, platelets have limited protein synthesis. By implication, in patients experiencing platelet disorders, platelet (dys)function is almost completely attributable to alterations in protein expression and dynamic difference…

PhysiologyPlatelet disorderblood plateletsproteomeBlood ProteinsDiseaseBiologyProteomicsBioinformaticsbleedingcardiovascular diseasesproteomicsHemostasisImmunologyProteomeAnimalsHumansPlatelethemorrhageTranscriptomeCardiology and Cardiovascular MedicineHomeostasisFunction (biology)Signal TransductionCirculation Research
researchProduct

Platelet function testing in pigs using the Multiplate® Analyzer.

2019

PLOS ONE 14(8), e0222010 (2019). doi:10.1371/journal.pone.0222010

Platelet AggregationSwinePhysiology030204 cardiovascular system & hematologyPlatelet inhibitionPharmacologyAntiplatelet Therapy0302 clinical medicineOral administrationAnimal CellsPig ModelsMedicine and Health SciencesMedicinePlateletOral AdministrationRoutes of AdministrationMammalsMultidisciplinaryPharmaceuticsQREukaryotaHematologyAnimal ModelsClopidogrelBody FluidsBloodExperimental Organism SystemsVertebratesMedicineAnatomyCellular Typesmedicine.drugResearch ArticleBlood PlateletsPlateletsPlatelet Function TestsScience610Research and Analysis Methods03 medical and health sciencesAnimal modelDrug TherapyAnimalsddc:610Platelet activationBlood CoagulationApplication methodsPharmacologyBlood CellsAspirinbusiness.industryOrganismsBiology and Life Sciences030208 emergency & critical care medicineCell BiologyPlatelet ActivationReference valuesAmniotesPurinergic P2Y Receptor AntagonistsAnimal StudiesbusinessPlatelet Aggregation InhibitorsPloS one
researchProduct

Different metabolic behavior of long-chain n-3 polyunsaturated fatty acids in human platelets.

1988

Abstract Whereas numerous studies deal with the effects and metabolism of eicosapentaenoic acid (20:5( n −3)) in platelets, very few concern docosahexaenoic acid (22:6( n −3)), although both acids are consumed in equal amounts from most fish fat. The present paper reports the modulation of 22:6( n −3) oxygenation as well as that of endogenous arachidonic acid (20:4( n −6)) in 22:6( n −3)-rich platelets. Like the oxygenation of 20:5( n −3), the lipoxygenation of 22:6( n −3) occurred at a low level when incubated alone, but was markedly increased in the presence of 20:4( n −6), suggesting a similar peroxide tone dependency. 20:5( n −3) could not replace 20:4( n −6) in the increasing 22:6( n −…

chemistry.chemical_classificationBlood PlateletsbiologyDocosahexaenoic AcidsChemistryLipoxygenaseBiophysicsThromboxanesMetabolismArachidonic AcidsIn Vitro TechniquesBiochemistryEicosapentaenoic acidLipoxygenasechemistry.chemical_compoundEndocrinologyBiochemistryEicosapentaenoic AcidDocosahexaenoic acidbiology.proteinHumansPlateletArachidonic acidUnsaturated fatty acidPolyunsaturated fatty acidBiochimica et biophysica acta
researchProduct

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus

2019

Background. Management of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available. Methods. Given this, an expert panel endorsed by the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on Thrombosis and Haemostasis was set up to produce a formal consensus, according to the RAND method, in order to issue clinical recommendations about the platelet (PLT) cut-off for safe administration of low molecular weight heparin (LMWH) in thrombocytopenic (PLT <100×…

venous thrombosis thrombocytopenia blood cancer anticoagulant treatment consensusanticoagulantsblood cancerblood plateletsvenous thromboembolismthrombocytopeniaHeparin Low-Molecular-Weightheparinplatelet countanticoagulant treatmentSettore MED/15 - MALATTIE DEL SANGUEVenous thromboembolism haematological malignancythrombocytopeniaconsensuslow-molecular-weightOriginal Articlehematologic neoplasmscardiovascular diseasesvenous thrombosishumansanticoagulant treatment; blood cancer; consensus; thrombocytopenia; venous thrombosis; anticoagulants; blood platelets; heparin low-molecular-weight; humans; platelet count; consensus; hematologic neoplasms; thrombocytopenia; venous thromboembolismAnticoagulant treatment; Blood cancer; Consensus; Thrombocytopenia; Venous thrombosis
researchProduct